Clinical Trial Update: SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism [Phase 3]

View source ↗

Summary

This document notes the completion of the Phase 3 SENSOR trial evaluating cinacalcet for secondary hyperparathyroidism in patients on haemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperparathyroidism

Drugs mentioned

• cinacalcet (cinacalcet hydrochloride)

Snippet

Sponsor: Amgen | Conditions: Secondary Hyperparathyroidism, End Stage Renal Disease | Phase 3 | Status: COMPLETED